vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and ORRSTOWN FINANCIAL SERVICES INC (ORRF). Click either name above to swap in a different company.

ORRSTOWN FINANCIAL SERVICES INC is the larger business by last-quarter revenue ($64.6M vs $33.4M, roughly 1.9× Ginkgo Bioworks Holdings, Inc.). Over the past eight quarters, ORRSTOWN FINANCIAL SERVICES INC's revenue compounded faster (39.3% CAGR vs -6.2%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

Orrstown Financial Services Inc is a US regional bank holding company headquartered in Shippensburg, Pennsylvania. It offers a full range of retail and commercial banking solutions including deposit accounts, personal and business loans, mortgages, and wealth management services, primarily serving customers across central Pennsylvania and northern Maryland.

DNA vs ORRF — Head-to-Head

Bigger by revenue
ORRF
ORRF
1.9× larger
ORRF
$64.6M
$33.4M
DNA
Faster 2-yr revenue CAGR
ORRF
ORRF
Annualised
ORRF
39.3%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
DNA
DNA
ORRF
ORRF
Revenue
$33.4M
$64.6M
Net Profit
$21.8M
Gross Margin
Operating Margin
-211.9%
Net Margin
33.8%
Revenue YoY
-23.8%
Net Profit YoY
19.1%
EPS (diluted)
$-1.41
$1.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
ORRF
ORRF
Q1 26
$64.6M
Q4 25
$33.4M
$64.9M
Q3 25
$38.8M
$64.4M
Q2 25
$49.6M
$62.4M
Q1 25
$48.3M
$60.4M
Q4 24
$43.8M
$61.8M
Q3 24
$89.0M
$64.1M
Q2 24
$56.2M
$33.3M
Net Profit
DNA
DNA
ORRF
ORRF
Q1 26
$21.8M
Q4 25
$21.5M
Q3 25
$-80.8M
$21.9M
Q2 25
$-60.3M
$19.4M
Q1 25
$-91.0M
$18.1M
Q4 24
$13.7M
Q3 24
$-56.4M
$-7.9M
Q2 24
$-217.2M
$7.7M
Operating Margin
DNA
DNA
ORRF
ORRF
Q1 26
Q4 25
-211.9%
42.3%
Q3 25
-231.8%
43.0%
Q2 25
-132.1%
39.6%
Q1 25
-184.1%
37.7%
Q4 24
-236.3%
27.7%
Q3 24
-62.0%
-15.4%
Q2 24
-396.7%
29.5%
Net Margin
DNA
DNA
ORRF
ORRF
Q1 26
33.8%
Q4 25
33.1%
Q3 25
-207.9%
34.0%
Q2 25
-121.6%
31.2%
Q1 25
-188.2%
29.9%
Q4 24
22.1%
Q3 24
-63.3%
-12.3%
Q2 24
-386.4%
23.3%
EPS (diluted)
DNA
DNA
ORRF
ORRF
Q1 26
$1.12
Q4 25
$-1.41
$1.11
Q3 25
$-1.45
$1.13
Q2 25
$-1.10
$1.01
Q1 25
$-1.68
$0.93
Q4 24
$-1.91
$0.35
Q3 24
$-1.08
$-0.41
Q2 24
$-4.23
$0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
ORRF
ORRF
Cash + ST InvestmentsLiquidity on hand
$422.6M
$161.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$508.6M
$603.2M
Total Assets
$1.1B
$5.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
ORRF
ORRF
Q1 26
$161.8M
Q4 25
$422.6M
Q3 25
$495.5M
Q2 25
$559.4M
Q1 25
$325.3M
Q4 24
$561.6M
Q3 24
$616.2M
Q2 24
$730.4M
Stockholders' Equity
DNA
DNA
ORRF
ORRF
Q1 26
$603.2M
Q4 25
$508.6M
$591.5M
Q3 25
$559.8M
$571.9M
Q2 25
$613.0M
$548.4M
Q1 25
$647.4M
$532.9M
Q4 24
$716.1M
$516.7M
Q3 24
$797.9M
$516.2M
Q2 24
$833.1M
$278.4M
Total Assets
DNA
DNA
ORRF
ORRF
Q1 26
$5.6B
Q4 25
$1.1B
$5.5B
Q3 25
$1.2B
$5.5B
Q2 25
$1.2B
$5.4B
Q1 25
$1.3B
$5.4B
Q4 24
$1.4B
$5.4B
Q3 24
$1.5B
$5.5B
Q2 24
$1.6B
$3.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
ORRF
ORRF
Operating Cash FlowLast quarter
$-47.7M
Free Cash FlowOCF − Capex
$-47.7M
FCF MarginFCF / Revenue
-142.8%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
ORRF
ORRF
Q1 26
Q4 25
$-47.7M
$74.7M
Q3 25
$-31.6M
$22.8M
Q2 25
$-40.3M
$24.5M
Q1 25
$-51.5M
$11.0M
Q4 24
$-42.4M
$35.0M
Q3 24
$-103.5M
$7.5M
Q2 24
$-84.4M
$6.4M
Free Cash Flow
DNA
DNA
ORRF
ORRF
Q1 26
Q4 25
$-47.7M
$70.5M
Q3 25
$22.3M
Q2 25
$-40.3M
$23.7M
Q1 25
$-59.1M
$8.6M
Q4 24
$-56.1M
$33.4M
Q3 24
$-118.6M
$7.1M
Q2 24
$-111.4M
$6.4M
FCF Margin
DNA
DNA
ORRF
ORRF
Q1 26
Q4 25
-142.8%
108.6%
Q3 25
34.7%
Q2 25
-81.2%
37.9%
Q1 25
-122.4%
14.3%
Q4 24
-128.0%
54.0%
Q3 24
-133.2%
11.1%
Q2 24
-198.2%
19.2%
Capex Intensity
DNA
DNA
ORRF
ORRF
Q1 26
Q4 25
0.0%
6.5%
Q3 25
0.0%
0.8%
Q2 25
0.1%
1.3%
Q1 25
15.8%
3.8%
Q4 24
31.3%
2.6%
Q3 24
16.9%
0.6%
Q2 24
48.1%
0.1%
Cash Conversion
DNA
DNA
ORRF
ORRF
Q1 26
Q4 25
3.48×
Q3 25
1.04×
Q2 25
1.26×
Q1 25
0.61×
Q4 24
2.55×
Q3 24
Q2 24
0.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

ORRF
ORRF

Net Interest Income$49.0M76%
Noninterest Income$15.6M24%

Related Comparisons